Some cancer cells remain trapped in an immature state, allowing them to keep reproducing and sustaining tumor growth. SLHMs is developing a new approach designed to interrupt that cycle.

Our research focuses on a biological pathway that may encourage these cancer cells to mature, stop renewing themselves, or become more vulnerable to treatment. We are building from a research compound that has already demonstrated promising activity in laboratory studies.

The next step is to transform that scientific starting point into a safer, more potent, patentable drug candidate with the characteristics needed for future clinical development.

Because metastatic tumor cells may spread through the cerebrospinal fluid, our treatment is being designed for direct delivery into this fluid. This approach is intended to place the medicine closer to the disease while addressing an area that can be difficult to reach with conventional therapies.